| Dr Kathryn D Wease, MD | |
|
3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 | |
| (248) 691-8646 | |
| Not Available |
| Full Name | Dr Kathryn D Wease |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 30 Years |
| Location | 3601 W 13 Mile Rd, Royal Oak, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811979263 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 4301063278 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital Royal Oak | Royal oak, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospital Consultants Pc | 5991698185 | 43 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint Breast Cancer Risk of Recurrence test and the BluePrint Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar.
The Prostate Cancer Foundation (PCF) announces 3 new Challenge Awards to support discoveries for the treatment of lethal prostate cancer.
What's clear is that committee Democrats moved awfully far in the name of compromise. They offered more in Medicare cuts than Simpson-Bowles did -; or than Obama did with Boehner, for that matter -; and accepted less in the way of tax increases than those two proposals. For their part, Republicans moved off their position of complete intransigence on taxes. Then they refused to budge.
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
› Verified 4 days ago
| Entity Name | Hospital Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073543013 PECOS PAC ID: 5991698185 Enrollment ID: O20040203000289 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint Breast Cancer Risk of Recurrence test and the BluePrint Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar.
The Prostate Cancer Foundation (PCF) announces 3 new Challenge Awards to support discoveries for the treatment of lethal prostate cancer.
What's clear is that committee Democrats moved awfully far in the name of compromise. They offered more in Medicare cuts than Simpson-Bowles did -; or than Obama did with Boehner, for that matter -; and accepted less in the way of tax increases than those two proposals. For their part, Republicans moved off their position of complete intransigence on taxes. Then they refused to budge.
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kathryn D Wease, MD 3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 Ph: (248) 691-8646 | Dr Kathryn D Wease, MD 3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 Ph: (248) 691-8646 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint Breast Cancer Risk of Recurrence test and the BluePrint Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar.
The Prostate Cancer Foundation (PCF) announces 3 new Challenge Awards to support discoveries for the treatment of lethal prostate cancer.
What's clear is that committee Democrats moved awfully far in the name of compromise. They offered more in Medicare cuts than Simpson-Bowles did -; or than Obama did with Boehner, for that matter -; and accepted less in the way of tax increases than those two proposals. For their part, Republicans moved off their position of complete intransigence on taxes. Then they refused to budge.
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
› Verified 4 days ago
Dr. Cristina Greulich, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Saketh Tummala, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Richard John Bloomingdale, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-4163 Fax: 248-898-5596 | |
Dr. Ioana D Pencu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Parag Somalingam, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Alice Kathleen Makris, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Chloe Habean Kim, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 |